Serum levels of interleukin-10 and interleukin-6 in patients with lung cancer - PubMed (original) (raw)
Affiliations
- PMID: 8841501
Clinical Trial
Serum levels of interleukin-10 and interleukin-6 in patients with lung cancer
A Wojciechowska-Lacka et al. Neoplasma. 1996.
Abstract
Since the enhanced production of IL-10 by human bronchogenic carcinoma has already been documented, in the present study serum levels of IL-10 were measured serially in patients with lung cancer undergoing radiotherapy. Thirty-one full diagnosed cancer patients underwent the radiotherapy procedures. The interleukin-10 (IL-10) and interleukin-6 (IL-6) serum levels were measured before therapy and after 3, 6 and 12 months after therapy. The interleukins concentrations were evaluated using a solid phase sandwich Enzyme-Linked-Immuno-Sorbent-Assay (ELISA). In all patients the serum levels of IL-10 have been found elevated. Due to the treatment they progressively declined to almost normal ranges in responders, while they remained elevated in non-responders. Serum levels of interleukin-6 have been elevated in the majority of our patients. After 12 months observation they also decreased, mainly in patients responding to the treatment. No correlation between serum IL-10 and IL-6 level has been found. The importance of serum IL-6 determination in lung cancer patients monitoring has already been established. The present study shows, that in spite of still unclear role of IL-10 in the process of carcinogenesis, it may be considered as a prognostic factor in lung cancer.
Similar articles
- Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome.
Galizia G, Lieto E, De Vita F, Romano C, Orditura M, Castellano P, Imperatore V, Infusino S, Catalano G, Pignatelli C. Galizia G, et al. J Interferon Cytokine Res. 2002 Apr;22(4):473-82. doi: 10.1089/10799900252952262. J Interferon Cytokine Res. 2002. PMID: 12034030 Retracted. Clinical Trial. - Prognostic value of serial serum interleukin-6 level estimation in patients with lung cancer: a preliminary report.
Wojciechowska-Lacka A, Adamiak E, Stryczynska G, Lacki JK. Wojciechowska-Lacka A, et al. Yale J Biol Med. 1997 Mar-Apr;70(2):139-48. Yale J Biol Med. 1997. PMID: 9493846 Free PMC article. Clinical Trial. - Combination of IL-6, IL-10, and MCP-1 with traditional serum tumor markers in lung cancer diagnosis and prognosis.
Pan YW, Zhou ZG, Wang M, Dong JQ, Du KP, Li S, Liu YL, Lv PJ, Gao JB. Pan YW, et al. Genet Mol Res. 2016 Nov 3;15(4). doi: 10.4238/gmr15048949. Genet Mol Res. 2016. PMID: 27819723 - Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy.
Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai YH, Chen YM, Huang MS, Chen HL, Li YJ, Yang PC, Chen CJ, Hsiung CA, Su WC. Chang CH, et al. Int J Cancer. 2013 May 1;132(9):1977-85. doi: 10.1002/ijc.27892. Epub 2012 Oct 29. Int J Cancer. 2013. PMID: 23034889 - Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy - Association of interleukin-8 and VEGF with survival.
Crohns M, Saarelainen S, Laine S, Poussa T, Alho H, Kellokumpu-Lehtinen P. Crohns M, et al. Cytokine. 2010 Apr;50(1):30-6. doi: 10.1016/j.cyto.2009.11.017. Epub 2009 Dec 30. Cytokine. 2010. PMID: 20044268
Cited by
- Polymorphisms of interleukin-10 promoter are not associated with prognosis of advanced gastric cancer.
Liu J, Song B, Wang JL, Li ZJ, Li WH, Wang ZH. Liu J, et al. World J Gastroenterol. 2011 Mar 14;17(10):1362-7. doi: 10.3748/wjg.v17.i10.1362. World J Gastroenterol. 2011. PMID: 21455338 Free PMC article. - The Treg/Th17 paradigm in lung cancer.
Duan MC, Zhong XN, Liu GN, Wei JR. Duan MC, et al. J Immunol Res. 2014;2014:730380. doi: 10.1155/2014/730380. Epub 2014 Apr 29. J Immunol Res. 2014. PMID: 24872958 Free PMC article. Review. - Serum and Bronchoalveolar Lavage Fluid Levels of Cytokines in Patients with Lung Cancer and Chronic Lung Disease: A Prospective Comparative Study.
Hogea P, Tudorache E, Fira-Mladinescu O, Marc M, Velescu D, Manolescu D, Bratosin F, Rosca O, Mavrea A, Oancea C. Hogea P, et al. J Pers Med. 2023 Jun 14;13(6):998. doi: 10.3390/jpm13060998. J Pers Med. 2023. PMID: 37373987 Free PMC article. - Therapeutical measures to control airway tolerance in asthma and lung cancer.
Andreev K, Graser A, Maier A, Mousset S, Finotto S. Andreev K, et al. Front Immunol. 2012 Jul 26;3:216. doi: 10.3389/fimmu.2012.00216. eCollection 2012. Front Immunol. 2012. PMID: 22855687 Free PMC article. - Expression of interleukin-11 and interleukin-11 receptor alpha in human colorectal adenocarcinoma; immunohistochemical analyses and correlation with clinicopathological factors.
Yamazumi K, Nakayama T, Kusaba T, Wen CY, Yoshizaki A, Yakata Y, Nagayasu T, Sekine I. Yamazumi K, et al. World J Gastroenterol. 2006 Jan 14;12(2):317-21. doi: 10.3748/wjg.v12.i2.317. World J Gastroenterol. 2006. PMID: 16482637 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical